ReviewPolymers2026
Green Synthesis and Functional Design of Polypyrrole-Based Nanomedicines for Cancer Theranostics: A Critical Review and Sustainability-Guided Perspective.
Review in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nanomedicine has advanced cancer theranostics via targeted delivery and phototherapy, yet many high-performance systems rely on inorganic or metal-intensive materials synthesized through energy-demanding routes, raising concerns about biocompatibility, environmental accumulation, and sustainability. This review re-evaluates polypyrrole (PPy)-based nanomedicines from a green chemistry perspective, shifting focus from performance-centric optimization to sustainability-guided design. PPy, an organic conductive polymer with near-infrared photothermal activity and structural tunability, offers a promising platform. However, pristine PPy suffers from limited functionality, poor biodegradability, and insufficient reactive oxygen species (ROS) generation. Reported FeCl
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.